Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Provided By GlobeNewswire
Last update: Aug 31, 2025
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants
93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics
Read more at globenewswire.com
